These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7111181)

  • 1. [Biological availability of two theophylline preparations (author's transl)].
    Kaik G
    Prax Klin Pneumol; 1982 Jun; 36(6):294-6. PubMed ID: 7111181
    [No Abstract]   [Full Text] [Related]  

  • 2. [Theophylline therapy in obstructive respiratory diseases. 1. Bioavailability and pharmacokinetics of various theophylline preparations (author's transl)].
    Wemhöner S; Oellerich M; Sybrecht G
    Prax Klin Pneumol; 1981 Jan; 35(1):36-41. PubMed ID: 7208408
    [No Abstract]   [Full Text] [Related]  

  • 3. [Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)].
    Wiessmann KJ
    Arzneimittelforschung; 1980; 30(2):329-32. PubMed ID: 7378114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimizing therapy with theophylline preparations in obstructive ventilation disorders. 3. Prediction of theophylline clearance with a simple pharmacokinetic method and comparison of bioavailability of various theophylline retard preparations].
    Ranke C; Schmidt G; Oellerich M; Sybrecht GW
    Prax Klin Pneumol; 1983 Mar; 37(3):99-108. PubMed ID: 6856564
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of two sustained-release theophylline preparations in adult patients with obstructive airways disease.
    Harkaway PS; Conlon PF; Hirsh JD; Allen WT
    J Clin Pharmacol; 1985 Sep; 25(6):444-7. PubMed ID: 4056079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Theophylline therapy in obstructive respiratory diseases. 2. Theophyllin-retard preparations for the long-term treatment of non-smokers with or without cardiac insufficiency (author's transl)].
    Wemhöner S; Oellerich M; Sybrecht G
    Prax Klin Pneumol; 1981 Jan; 35(1):42-6. PubMed ID: 6782562
    [No Abstract]   [Full Text] [Related]  

  • 7. [Possibilities for optimizing therapy with theophylline preparations. I. On the pharmacokinetics of theophylline preparations].
    Wiesner B; Sehrt I; Iwainsky H
    Z Erkr Atmungsorgane; 1984; 162(1):3-10. PubMed ID: 6719957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of bioavailability and pharmacokinetic profiles between Theodur and a new sustained-release theophylline formulation].
    Morishita M; Nagai T; Ishizaki T; Suganuma T; Kushida K; Minegishi A
    Arerugi; 1986 Nov; 35(11):1099-104. PubMed ID: 3827603
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bioavailability of oral theophylline preparations (author's transl)].
    Plavsić F; Vrhovac B; Bakran I
    Lijec Vjesn; 1978 Oct; 100(10):610-2. PubMed ID: 745496
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
    Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
    Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theophylline-mexiletine interaction: a case report.
    Kendall JD; Chrymko MM; Cooper BE
    Pharmacotherapy; 1992; 12(5):416-8. PubMed ID: 1437703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of a serum concentration-oriented dosage of a theophylline depot preparation in ambulatory patients with chronic obstructive lung disease].
    Harder S; Staib AH; Stauder J
    Prax Klin Pneumol; 1985 Jun; 39(6):193-6. PubMed ID: 4022931
    [No Abstract]   [Full Text] [Related]  

  • 13. Slow-release theophylline for the management of chronic asthma.
    Hendeles L; Weinberger M
    Singapore Med J; 1985 Feb; 26(1):83-90. PubMed ID: 3895446
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical results obtained from a new controlled release theophylline preparation.
    Nolte D
    Br J Clin Pract Suppl; 1984; 32():14-7. PubMed ID: 6432017
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tolerance of a new oral long-acting theophylline in patients with obstructive airway diseases].
    Nolte D; Dusik B
    Fortschr Med; 1983 Jul; 101(25):1203-6. PubMed ID: 6884955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Obstructive airway diseases. Basic therapy with pure theophylline in retard form].
    Pollert I
    Fortschr Med; 1982 Mar; 100(12):547-50. PubMed ID: 7042500
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comparative bioavailability of 2 oral theophylline sustained-release preparations].
    Tritthart W; Lücker PW; Fáy E; Buchebner J
    Arzneimittelforschung; 1983; 33(11):1603-6. PubMed ID: 6686457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of obstructive respiratory tract diseases. Study of afonilum retard in 3,512 patients].
    Eichhorn J; Perré R
    Med Welt; 1982 Dec; 33(50):1834-7. PubMed ID: 6762480
    [No Abstract]   [Full Text] [Related]  

  • 19. Circadian variation in the absorption of three sustained release theophylline products in asthmatic children and the effect of food on absorption of Somophyllin-CRT.
    Birkett DJ; Coulthard KP; Lines D; Grgurinovich N
    Br J Clin Pract Suppl; 1984; 35():17-23. PubMed ID: 6433954
    [No Abstract]   [Full Text] [Related]  

  • 20. [Serum levels and urinary and fecal excretion of ethamicylin HCI (solucylin). Oral and intravenous administration (author's transl)].
    Torres A; Rovira J; Zapatero D; Vilageliu J; Ribalta M; Bruseghini L
    Arch Farmacol Toxicol; 1980 Dec; 6(3):237-46. PubMed ID: 7305455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.